Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil
Jan Mikkelsen, Chief Executive Officer of Ascendis, stated "While we are pleased with the pharmacokinetic results observed in this study, and believe they affirm the potential of our TransCon technology, TransCon Treprostinil did not reproduce the tolerability profile observed in preclinical studies." Mr. Mikkelsen continued, "As we look forward to the remainder of 2015, we plan to finalize and report topline data from our Phase 2 pediatric study of TransCon Growth Hormone by mid-year and prepare for the initiation of our Phase 3 pediatric study in mid-2016. We will also continue to develop our internal pipeline of therapeutics for orphan diseases."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.